Log in

RegulatoryCNBC-TV18

Natco Pharma gets seven USFDA observations at Hyderabad plant

Negative-336 sources

GreyOak summary

Natco Pharma received seven observations from the US FDA following an inspection of its formulations manufacturing facility in Kothur, Hyderabad, conducted between November 12 and November 20, 2026. The observations were issued in Form 483, which the company believes are procedural in nature. Natco Pharma stated it is confident of addressing these observations comprehensively within the stipulated timelines.

What it affects

  • Received seven USFDA observations at Hyderabad plant.Rolling sentiment Negative -35

Source

Reported by CNBC-TV18

  • Business Today
  • BusinessLine
  • Economic Times
  • Economic Times
  • Economic Times
  • CNBC-TV18

More Natco Pharma news

All Natco Pharma news →

The company today

Price, day change, sector and market cap of the companies this story names
CompanyPriceDay changeSectorMarket cap
Natco PharmaNATCOPHARM · NSE₹814.30−0.93%Healthcare₹15,974 crore

Prices as of ; the last session's close when the market is shut. Research, not investment advice.

Latest market news

News Intelligence →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy